Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2021 | RESMAIN: HDAC inhibitor resminostat for CTCL

Rudolf Stadler • 15 Oct 2021
EORTC CLTF 2021
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases Resminostat
RESMAIN

Rudolf Stadler, MD, PhD, University Medical Center Minden, Minden, Germany, discusses findings from the Phase II RESMAIN trial (NCT02953301) evaluating resminostat as a maintenance therapy for patients with advanced-stage mycosis fungoides or Sézary syndrome, two subtypes of cutaneous T-cell lymphoma (CTCL). Prof. Stadler reports that 190 patients will have been recruited to the trial by the end of the year and will final results will be published in 2023. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

More from Rudolf Stadler

1:25
PARCT: atezolizumab for CTCL and next steps
Rudolf Stadler • 15 Oct 2021
1:27
Lacutamab for CTCL
Rudolf Stadler • 15 Oct 2021
1:15
Advances in understanding the molecular pathogenesis of CTCL
Rudolf Stadler • 15 Oct 2021
1:02
The importance of maintenance therapy for CTCL
Rudolf Stadler • 15 Oct 2021

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals